| Biomarker ID | 821 |
| PMID | 22127895 |
| Year | 2012 |
| Biomarker | Methylation Status of AIM1 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Decreased hypermethylation in progression |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR = 0.4 (95% CI: 0.18-0.89) ; Multivariate: HR = 0.45 (95% CI: 0.2, 1.0) |
| Effect on Pathways | NA |
| Experiment | Time To Progression |
| Type of Biomarker | Prognostic |
| Cohort | 95 prostate cancer patients all with a Gleason score of 3 + 4 = 7 and a minimum follow-up period of 8 years. 48 patients had experienced recurrence |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p = 0.02 ; Multivariate: p = 0.05 |
| Method Used | Quantitative Methylation Specific PCR (QMSP) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CRYBG1 |